<DOC>
	<DOCNO>NCT02404337</DOCNO>
	<brief_summary>Oral treatment betaine conventionally use patient inherited homocystinurias . These condition include first group patient cystathionine β-synthase ( CBS ) deficiency second group patient remethylation defect . The aim betaine therapy reduce level total plasma homocysteine . Daily dosage rhythm administration propose literature vary 100 250 mg / kg / 2 4 dos . These dosage base validate data several publication mention much high dosage particularly total homocysteine control . These practice may unnecessary even detrimental give fact high dos betaine could example lead secondary folate deficiency .</brief_summary>
	<brief_title>Betaine METABOLISM OF PATIENTS With Homocystinuria</brief_title>
	<detailed_description>Oral treatment betaine conventionally use patient inherited homocystinurias . These condition include first group patient cystathionine β-synthase ( CBS ) deficiency second group patient remethylation defect . The aim betaine therapy reduce level total plasma homocysteine . Daily dosage rhythm administration propose literature vary 100 250 mg / kg / 2 4 dos . These dosage base validate data several publication mention much high dosage particularly total homocysteine control . These practice may unnecessary even detrimental give fact high dos betaine could example lead secondary folate deficiency .</detailed_description>
	<mesh_term>Homocystinuria</mesh_term>
	<mesh_term>Betaine</mesh_term>
	<criteria>≥1 year child &lt; 18 year , homocystinuria confirm enzymatically molecularly divide 2 group : CBS deficiency remethylation defect ( CbIC defect MTHFR deficiency ) Diagnosis homocystinuria since 1 year Continuous treatment hyperhomocysteinemia last 12 month Deficits cystathionine betasynthase B6responsive pregnancy breastfeed Young pubescent girl use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>